Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks is involved in synthetic biology, providing data-driven R&D services for various industries including agriculture and biopharma. Self-described as the Organism Company.

Ginkgo Bioworks

Grow by Ginkgo

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Synlogic

Empede Capital

General Atlantic

Y Combinator

Bill Gates

T. Rowe Price

Viking Global Investors

Cascade Investment

Illumina

Ginkgo Bioworks, Inc.

This week on Foundry Theory! What is it about biotech R&D that makes collaboration challenging? How can we make it easier?
https://hubs.la/Q02NTygX0

We're excited to welcome Patrick Boyle as an Advisor at SIC. Patrick is currently Ginkgo Bioworks, Inc.'s Chief Scientific Officer, having been at Ginkgo from the earliest days as one of the first full time scientist hires at the company in 2012. As a pioneer in synthetic and computational biology, Patrick brings unparalleled expertise to our extended network. His experience in developing Ginkgo’s codebase and driving customer-focused business development is a powerful addition to our firm’s toolkit. Welcome Patrick!

https://lnkd.in/eZjsX4ZQ

I tried to go a bit sassy and provocative in this week's video, asking "which type of nerds are the coolest?"

My professional opinion: it's the bio nerds

We're #hiring a new Director, Infrastructure Enablement in United States. Apply today or share this post with your network.

Ginkgo is pleased to announce Max Breet, Director of Business Development EMEA, will be joined by other industry experts at this year's upcoming GLOBSEC Forum to discuss the growing need for robust biosecurity infrastructure and what it will take to get us there!

#GLOBSEC2024 #GLOBSECPRAGUE

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover		0.11 -	0.15 33.47%	0.19 24.14%	0.15 19.74%
cash conversion cycle		-145.76 -	160.75 210.29%	52.13 67.57%	14.95 71.32%
cash per share		0.26 -	1.14 344.52%	0.78 31.25%	0.49 37.73%
company equity multiplier		1.46 -	1.38 5.99%	1.46 6.31%	1.52 3.79%
days of inventory outstanding		63.97 -	9.46 85.21%	7.80 17.57%	0.15 98.02%
days of payables outstanding		324.83 -	23.05 92.90%	18.68 18.95%	31.27 67.42%
days of sales outstanding		115.10 -	174.34 51.46%	63.01 63.86%	46.07 26.88%
dividend yield
ebit per revenue	-1.32 -	-1.79 35.28%	-5.83 225.93%	-4.62 20.63%	-2.67 42.19%
ebt per ebit	1.67 -	0.91 45.57%	1.01 10.35%	0.96 4.47%	1.33 38.31%
effective tax rate	-0.00 -	-0.02 8,142.52%	0.00 105.32%	0.01 779.76%	0.00 98.88%
enterprise value multiple		-136.40 -	-5.21 96.18%	-0.90 82.69%	-4.29 376.55%
fixed asset turnover		0.63 -	2.15 241.06%	0.67 68.99%	0.63 5.18%
free cash flow per share	-0.05 -	-0.13 189.54%	-0.23 75.01%	-0.18 20.54%	-0.17 4.62%
gross profit margin	1 -	0.80 20.36%	0.59 26.32%	0.57 2.43%	0.57 0.91%
interest coverage	-29.57 -	-57.45 94.27%	-770.53 1,241.13%	-20.84K 2,604.53%	-7.23K 65.31%
inventory turnover		5.71 -	38.58 576.07%	46.80 21.31%	2.37K 4,954.92%
long term debt to capitalization		0.03 -	0.01 57.80%	0.19 1,218.03%	0.17 12.52%
net income per ebt	1.00 -	1.02 1.49%	1.00 1.57%	0.99 0.63%	1.00 0.71%
net profit margin	-2.21 -	-1.65 25.27%	-5.85 254.01%	-4.41 24.66%	-3.55 19.47%
operating cash flow per share	-0.03 -	-0.09 204.12%	-0.19 104.07%	-0.15 19.53%	-0.15 1.18%
operating cycle		179.07 -	183.80 2.64%	70.81 61.47%	46.22 34.72%
operating profit margin	-1.32 -	-1.79 35.28%	-5.83 225.93%	-4.62 20.63%	-2.67 42.19%
payables turnover		1.12 -	15.84 1,309.42%	19.54 23.38%	11.67 40.27%
pretax profit margin	-2.21 -	-1.63 26.37%	-5.86 259.66%	-4.44 24.18%	-3.55 20.03%
price fair value		32.57 -	7.51 76.95%	1.63 78.23%	3.00 83.26%
receivables turnover		3.17 -	2.09 33.98%	5.79 176.69%	7.92 36.77%
return on assets		-0.19 -	-0.89 372.49%	-0.83 6.47%	-0.54 35.37%
return on capital employed		-0.23 -	-0.94 314.83%	-0.93 1.15%	-0.45 52.04%
return on equity		-0.27 -	-1.22 344.20%	-1.21 0.57%	-0.81 32.92%
total debt to capitalization		0.04 -	0.02 57.61%	0.20 1,248.07%	0.18 11.11%

COM:GINKGOBIOWORKS

Ginkgo Bioworks

Last Close

6.59

22/11 21:00

Market Cap

725.64M

Beta: -

Volume Today

129

Avg: -

Preview